CN113786376B - Eye cream composition with eye pattern removing effect and preparation method thereof - Google Patents
Eye cream composition with eye pattern removing effect and preparation method thereof Download PDFInfo
- Publication number
- CN113786376B CN113786376B CN202111126729.XA CN202111126729A CN113786376B CN 113786376 B CN113786376 B CN 113786376B CN 202111126729 A CN202111126729 A CN 202111126729A CN 113786376 B CN113786376 B CN 113786376B
- Authority
- CN
- China
- Prior art keywords
- eye
- skin
- percent
- removing effect
- wrinkles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000694 effects Effects 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000006071 cream Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000037303 wrinkles Effects 0.000 claims abstract description 100
- 241000237858 Gastropoda Species 0.000 claims abstract description 22
- 239000000706 filtrate Substances 0.000 claims abstract description 22
- 230000028327 secretion Effects 0.000 claims abstract description 21
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims abstract description 16
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims abstract description 15
- 241001090156 Huperzia serrata Species 0.000 claims abstract description 15
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims abstract description 15
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003974 emollient agent Substances 0.000 claims abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000002562 thickening agent Substances 0.000 claims abstract description 10
- 239000003755 preservative agent Substances 0.000 claims abstract description 8
- 230000002335 preservative effect Effects 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims abstract description 4
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 4
- 239000002537 cosmetic Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- -1 polydimethylsiloxane Polymers 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 claims description 2
- SADBYAVWGZIEFD-UHFFFAOYSA-L 2-octyl-1,3,2-dioxalumepane-4,7-dione Chemical compound C(CCC(=O)[O-])(=O)[O-].C(CCCCCCC)[Al+2] SADBYAVWGZIEFD-UHFFFAOYSA-L 0.000 claims description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 229910052582 BN Inorganic materials 0.000 claims description 2
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 108010000126 Gabolysat PC60 Proteins 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 240000007817 Olea europaea Species 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 229940048053 acrylate Drugs 0.000 claims description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 229940036350 bisabolol Drugs 0.000 claims description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 claims description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940100556 laureth-23 Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000010445 mica Substances 0.000 claims description 2
- 229910052618 mica group Inorganic materials 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940120511 oleyl erucate Drugs 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 229940047670 sodium acrylate Drugs 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940114926 stearate Drugs 0.000 claims description 2
- 229940100459 steareth-20 Drugs 0.000 claims description 2
- 229940100458 steareth-21 Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 239000000686 essence Substances 0.000 abstract description 7
- 206010040925 Skin striae Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 208000003464 asthenopia Diseases 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 83
- 230000002829 reductive effect Effects 0.000 description 27
- 230000008859 change Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 230000037394 skin elasticity Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 241000195493 Cryptophyta Species 0.000 description 12
- 210000004207 dermis Anatomy 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 230000003020 moisturizing effect Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 239000002344 surface layer Substances 0.000 description 4
- 241000218642 Abies Species 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 210000001595 mastoid Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 230000037393 skin firmness Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000257468 Asterias amurensis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241001504070 Huperzia Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010050637 Skin tightness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an eye cream composition with an eye pattern removing effect and a preparation method thereof. The eye-print removing effect eye cream comprises the following raw material components: 1.0 to 35.0 percent of eye-mark removing functional components, 5.0 to 40.0 percent of emollients, 0.5 to 30.0 percent of emulsifying agents, 0.5 to 20.0 percent of filling agents, 0.1 to 10.0 percent of thickening agents, 0.3 to 5.0 percent of preservative, 0.01 to 1.0 percent of daily essences and the balance of deionized water. The eye striae removing functional component of the invention consists of snail secretion filtrate, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and a huperzia serrata extract. The functional components for removing the eyestrain can act on deep layers of skin of eyes, effectively reduce the generation of wrinkles, smooth the existing wrinkles, have good eyestrain removing effect, effectively reduce the loss of skin moisture, maintain the elasticity and the compactness of the skin, and improve other aging phenomena of the skin around the eyes.
Description
Technical Field
The invention relates to a cosmetic composition and a preparation method and application thereof, belongs to the technical field of daily chemicals, and particularly relates to an eye cream composition with an eye pattern removing effect and a preparation method thereof.
Background
The fine lines of eyes refer to small fine lines and wrinkles formed by the fact that the skin of eyes is influenced by external environment to form free radicals, and collagen and active substances in normal cell membrane tissues are damaged by the free radicals and cells are oxidized.
With the aging, the skin is aged, the moisturizing effect and the barrier function of the skin are gradually weakened, the content of natural moisturizing factors is reduced, the skin around the eyes is thinnest, sebaceous glands and sweat glands are not available, the water retention capacity is poor, the water is easy to evaporate, and the skin water deficiency caused by the environment, seasons and self causes is always a major cause of the generation of fine wrinkles of the eyes.
Secondly, with the development of modern society, most people need to face computers and various bad habits such as frequent squinting eyes or blinking, which can easily cause aging of the skin of eyes to generate fine lines. Since both eyes are blinked for more than ten thousand times per day, skin and muscles around the eyes are naturally involved in such frequent blinking, and thus, eyelid slackening and frailty are easily caused, which is also the cause of easy formation of "wrinkles" around the eyes. Overuse of the eyes is also one of the main causes of fine lines around the eyes.
Furthermore, poor ocular blood circulation can also lead to the generation of fine lines. Because the skin of the eyes is thinner, the blood vessels in the opposite skin are thinner and fewer, so that nutrients and oxygen are more difficult to transport into skin cells, and capillary circulation around the eyes is easy to stagnate. In addition, as the age increases, the content of collagen and elastin of skin begins to gradually decrease, the skin lacks enough nutrition and vitality, the nutrition of the eye skin is difficult to supplement, the blood circulation is poor, the metabolism is also difficult, fine lines begin to appear, and finally the skin around the eyes is easy to age and wrinkle.
However, the existing eye pattern removing products on the market have various defects of unobvious effect, long effect period, large irritation and the like, so that the eye cream skin care product with better eye pattern removing performance and safety is provided, and the technical problem which is urgently needed to be solved by the current technicians in the field.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide an eye cream composition containing various functional components and capable of synergistically increasing the effect of removing wrinkles.
Another object of the present invention is to provide a method for preparing the eye cream composition with the effect of removing the wrinkles.
The technical scheme adopted by the invention is as follows.
An eye cream composition containing various eye wrinkle removing functional components and having eye wrinkle removing effects comprises the following raw material components by weight:
1.0-35.0% of an eye-mark removing functional component comprising: snail secretion filtrate 0.1-30%, palmitoyl tripeptide-1.1-30%, palmitoyl tetrapeptide-7.1-30% and Huperzia serrata extract 0.1-30%;
5.0-30.0% emollient;
0.5-30.0% of an emulsifier;
0.5-20.0% filler;
0.1-10.0% of a thickener;
0.3-5.0% preservative;
0.01-1.0% of daily essence;
and the balance of deionized water.
Furthermore, the eye wrinkle removing efficacy eye cream composition comprises the following components in terms of the total weight of the composition:
4.0-25% of eye wrinkle removing functional components, wherein the eye wrinkle removing functional components comprise: snail secretion filtrate 1-20%, palmitoyl tripeptide-1 1-20%, palmitoyl tetrapeptide-7 1-20% and Huperzia serrata extract 1-20%;
further, the eye-wrinkle-removing functional component comprises the following raw material components:
snail secretion filtrate 1-10%, palmitoyl tripeptide-1 1-10%, palmitoyl tetrapeptide-7 1-10% and Huperzia serrata extract 1-10%.
Further, the eye-wrinkle-removing functional component comprises the following raw material components:
snail secretion filtrate 1.0-5%, palmitoyl tripeptide-1.0-5%, palmitoyl tetrapeptide-7.0-5% and Huperzia serrata extract 1.0-5%.
Further, the emollient is selected from at least one of caprylic/capric triglyceride, squalane, avocado oil, shea butter, jojoba oil, glycerin, butylene glycol, hexylene glycol, 1, 2-pentanediol, methylpropanediol, C12-16 alcohol, polydimethylsiloxane, dimethiconol, PEG-11 methyl ether dimethicone, phytosterol canola oil glycerides, hydrogenated polyisobutylene, lecithin, polydecene, sodium hyaluronate, soybean oil, olive oil, isododecane, isohexadecane, stearyl alcohol, bisabolol, panthenol, behenyl alcohol. The content is selected from the range of 5-30%, preferably 10-18%.
The emulsifier is selected from at least one of olive oil PEG-7 esters, coconut oil PEG-10 esters, PEG-8 caprylic/capric glycerides, sorbitan olive oleate, stearic acid, palmitic acid, octyldodecanol, polysorbate-20, laureth-23, PEG-40 stearate, steareth-21, palmitols and mixtures of PEG-75 stearate and glyceryl stearate and steareth-20, tocopheryl acetate, soy lecithin PC60, mixtures of glyceryl stearate and PEG-75 stearate, oleyl erucate, PEG-30 dimerized hydroxystearate, cetostearyl ether-25. The content is selected from the range of 0.5-30%, preferably 0.5-10%.
The filler is at least one selected from titanium dioxide, mica, boron nitride, maltodextrin, polymethylsilsesquioxane, diatomite, kaolin, cellulose acetate, starch octyl aluminum succinate, talcum powder, barium sulfate and volcanic ash. The content is selected from the range of 0.2-20%, preferably from the range of 0.5-15%, most preferably from the range of 2% -10%.
The thickener is at least one selected from hydroxyethyl cellulose, xanthan gum, carbomer, sodium polyacrylate, acrylic acid (ester) copolymer, polymer EMT-10, polyacrylate crosslinked polymer-6, sodium acrylate/sodium acryloyldimethyl taurate copolymer, acrylic acid (ester) C10-30 alkanol acrylate crosslinked polymer, acrylamide/VP copolymer, polyethylene and gum arabic. The content is in the range of 0.3-8%, preferably 0.5-5%.
In addition, the invention also discloses a preparation method of the eye cream composition with the eye wrinkle removing effect, which comprises the following process steps:
1) Wetting and dispersing the thickener in water completely;
2) Adding the eye pattern removing effect composition, the emollient, the filler and the preservative into the mixed solution in the step 1), heating to 65 ℃, homogenizing for 3 minutes at 3000r/min to enable the mixture to be completely dispersed;
3) Adding the emulsifying agent and the daily essence into the step 2), homogenizing for 3 minutes at 3000r/min to completely emulsify, and heating to 65 ℃ to obtain the eye cream composition with the eye wrinkle removing effect.
In particular, the eye cream composition of the present invention having an anti-wrinkle effect has a pH in the range of 4 to 10, preferably a pH in the range of 5 to 8, and most preferably a pH in the range of 5 to 7.
Specifically, the eye-pattern-removing functional cosmetic composition can be in a solvent dispersion or suspension mode, can be in the form of emulsified particles or can be in the form of polymer packages.
Specifically, the eye cream composition with the eye wrinkle removing effect can be designed into other skin care product formulations, such as emulsion, essence, face cream, eye cream, body milk, gel and sun-proof milk.
By means of the technical scheme, the invention has the following advantages and beneficial technical effects:
1) The invention contains various cosmetic raw materials such as snail secretion filtrate, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and a huperzia serrata extract, which can effectively prevent and lighten wrinkles and tighten skin, can make the skin younger, smoother and more elastic, effectively remove eye wrinkles, and care the skin around eyes.
2) The eye striae removing functional component composition of the invention is preferably snail secretion filtrate, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and a huperzia serrata extract, and the most preferred composition proportion of cosmetics is found through the preferred combination and the efficacy test, so that the eyes are free from dark circles.
3) Compared with most of cosmetics sold in the market at present, the eye cream for removing the eye wrinkles provided by the embodiment of the invention has obvious synergistic effect, is suitable for more crowds with different skin types, and has wide application range, and after being used by a user, the eye cream for removing the eye wrinkles obviously reduces and the skin elasticity obviously increases. The components for tightening eyes and removing eye marks are mutually cooperated to achieve the effect of safely and effectively removing eye marks.
4) The novel eye wrinkle removing cosmetics can relieve the relaxation of skin around eyes and generate wrinkle phenomenon, and provide a plurality of ideal benefits for eye care so as to bring younger appearance.
Drawings
FIG. 1 shows the rate of change of the wrinkle area in the skin at the canthus before and after use of example 1;
FIG. 2 shows the rate of change of the wrinkle area ratio in the skin at the corners of the eyes before and after use in example 1;
FIG. 3 shows the rate of change of the Ra of skin wrinkles at the canthus before and after use of example 1;
FIG. 4 shows the rate of change of the skin elasticity R2 of the canthus before and after use of example 1;
FIG. 5 shows the rate of change of skin tightening at the canthus before and after use of example 1;
FIG. 6 shows a graph of the change in skin of the canthus before and after use of example 1 for a portion of a subject;
FIG. 7 shows the change rate of the wrinkle area of the skin at the canthus before and after the use of example 1 and comparative examples 1 to 8.
Detailed Description
The invention discloses an eye-mark removing eye cream composition containing various eye-mark removing effective components and a preparation method thereof. The eye wrinkle removing effect cream comprises the following raw material components:
1.0 to 35.0 percent of eye-mark removing functional components, 5.0 to 40.0 percent of emollients, 0.5 to 30.0 percent of emulsifying agents, 0.5 to 20.0 percent of filling agents, 0.1 to 10.0 percent of thickening agents, 0.3 to 5.0 percent of preservative, 0.01 to 1.0 percent of daily essences and the balance of deionized water.
The eye wrinkle removing effective component is prepared by mixing snail secretion filtrate, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and Huperzia serrata extract.
The snail secretion filtrate can permeate into subcutaneous tissue layers, contains various active ingredients, effectively moisturizes and maintains skin elasticity, and reduces fine lines; the extract of the Huperzia serrata also has the functions of moisturizing and preventing the generation of fine lines caused by the rupture of muscle fibers by improving the adhesion between cells; palmitoyl tripeptide-1 promotes strengthening of dermis, makes skin thicker, tightens the skin, and relieves wrinkles; palmitoyl tetrapeptide-7 restores the papillary dermis, smoothes wrinkles and improves skin tone and elasticity.
Specifically, the snail secretion filtrate is a mucus, an external bodily waste secreted by snails. The snail secretion filtrate contains high molecular weight proteins, low molecular weight proteins, glycosaminoglycans, inorganic compounds, low molecular weight antioxidants. Wherein, collagen contained in the snail secretion filtrate is an important connective tissue component of skin, and is structured with elastin for keeping skin tissue elasticity to form a complete skin, thereby having the efficacy of keeping moisture and reducing the damage of ultraviolet rays to the skin; the allantoin can effectively repair scars, help skin resist free radicals, has the effects of moisturizing, wound healing, anti-inflammation, cell regeneration stimulation and relaxation, and is a skin softener and an antioxidant; glucuronic acid can make the adhesive lipid on the epidermis surface layer of skin soft, so as to remove old cutin, accelerate cell regeneration, reduce skin wrinkles and scars, remove dark complexion, lighten color spots and resist damage of free radicals to skin. In short, the snail secretion filtrate contains various active ingredients, and is effective in increasing skin elasticity and reducing wrinkles.
The snail secretion filtrate in the embodiment of the invention is a commercial product.
The Abies starburst algae extract is rich in sulfated polysaccharide, and has effects of resisting oxidation and scavenging free radicals. Can induce and activate skin multifunctional barrier, regulate skin wettability, control skin barrier permeability, reduce skin moisture loss, supplement water and moisturize, improve intercellular adhesion, make skin tissue connection more compact and complete, and prevent wrinkle caused by myofiber fracture.
The preparation method of the Abies starburst algae extract in the embodiment of the invention comprises the following steps:
1) Selecting algae: selecting fresh Abies starburst algae, removing impurities such as grass sticks, silt and the like attached to the algae leaves, soaking in 75% ethanol solution for 15-30 min, and airing for later use;
2) Drying and powdering: drying the pretreated astronomical fir algae in the 1) in the environment of 50-80 ℃ for 36-48 hours until the moisture content in algae leaves is reduced to below 8%, taking out the dried astronomical fir algae, pulverizing into powder, and sieving with a 80-200 mesh sieve to obtain algae powder;
3) Foaming and ultrasonic treatment: mixing the algae powder in the step 2) with water according to the mass ratio of 1:20, foaming for 8 hours to obtain a mixed solution, placing the mixed solution into an ultrasonic cell crusher, and performing ultrasonic treatment for 6-8 hours under the condition of 200-500W of power to obtain an ultrasonic solution of the astrotrichia pastoris;
4) And (3) enzymolysis and fermentation: adding citric acid into the alga ultrasonic solution in the step 3), adjusting the pH value of the solution to 4.0-6.0, adding 6X 104-8X 104U/L pectase and 0.1X 104-1X 104U/L cellulase into the alga ultrasonic solution, and carrying out enzymolysis for 3-5 hours at 40-60 ℃; heating the hydrolyzed alga ultrasonic solution to boiling, inactivating enzyme for 5-20 minutes, and cooling to room temperature to obtain alga enzymolysis solution;
5) And (3) filtering, decompressing, distilling and collecting: adding 90% ethanol into the algae enzymolysis solution in the step 4), extracting for 12 hours at 30 ℃, filtering, taking filtrate, distilling under reduced pressure, and removing ethanol in the solution to obtain the asterias amurensis extract.
Palmitoyl tripeptide-1, also known as collagen, acts on the dermis layer, and can promote the synthesis of extracellular matrixes such as collagen and glycosaminoglycan, strengthen the dermis layer, make the skin thicker, tighten and ease wrinkles, has stronger ultraviolet radiation resistance, is a cosmetic raw material capable of effectively preventing and weakening wrinkles and tightening the skin, and can make the skin younger, smoother and more elastic.
Palmitoyl tetrapeptide-7 combines two palmitoyl extracellular matrix activators (tripeptides) -palmitoyl-GHK (tripeptides) and palmitoyl-GQPR (tetrapeptides), which have a regulatory effect on the epidermal and dermal genes, supporting the activation of the skin repair process, particularly the mastoid dermis, which is fragile and vulnerable to UV damage.
Palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 are commercially available products.
Palmitoyl tripeptide-1 in the eye wrinkle removing effect composition permeates into the dermis layer to tighten skin and relieve wrinkles; the snail secretion filtrate acts on the skin surface layer, so that the skin elasticity is effectively increased, and the wrinkles are reduced; palmitoyl tetrapeptide-7 contains extracellular matrix activin, and regulates the activation and repair of epidermal and dermal genes; the extract of the Huperzia serrata can supplement water and moisturize the skin, so that the skin is compact and elastic.
The various active ingredients act on the dermis layer from the surface layer of the skin, so that the skin elasticity is effectively increased, the occurrence of wrinkles is slowed down, the fragile skin around the eyes is effectively strengthened, the effect of removing the eye marks is good, and the effects of moisturizing, repairing ultraviolet injury and the like are achieved.
The invention is illustrated by the following examples which are given for further illustration of the invention and are not intended to limit the scope of the invention. Some insubstantial modifications and adaptations of the invention by others are within the scope of the invention.
The following percentages (%) are mass percentages unless otherwise indicated. All raw material components of the invention are commercial products.
Examples 1 to 4 and blank examples
An eye cream with eye wrinkle removing effect comprises the following raw materials in proportion as shown in table 1.
TABLE 1 raw material composition ratios (unit: mass%) of examples 1 to 4 and blank examples
The preparation process flow of the eye moisturizing eye cream provided by the embodiment of the invention is as follows:
1) Wetting and dispersing the thickener in water completely to obtain a mixed solution;
2) Adding the eye pattern removing functional components, the emollient, the filler and the preservative into the mixed solution in the step 1), heating to 65 ℃, homogenizing for 3 minutes at 3000r/min to enable the components to be completely dispersed;
3) Adding the emulsifying agent and the daily essence into the step 2), homogenizing for 3 minutes at 3000r/min to completely emulsify, and heating to 65 ℃ to obtain the eye cream composition with the eye wrinkle removing effect.
Effect verification test example
Test 1 of the effect of removing eye marks and tightening and increasing skin elasticity
1. The tester: 30 healthy people (20-45 years old), using example 1, women: the outer canthus wrinkles on both sides are rated 1 to 3 (according to the japanese wrinkle grade); the face has no obvious redness, skin damage, scars and the like;
2. test part: periocular region;
3. test instrument: visia is used for facial image acquisition. Visia-CR is used for facial image acquisition and wrinkle analysis. Primos is used for facial image acquisition and wrinkle analysis. Skin elasticity tester MPA580 is used to detect skin elasticity. Skin elasticity tester->MPA580 is used to detect skin firmness.
4. The test indexes are as follows: the change rate of the area of the canthus wrinkles, the change rate of the Ra of the canthus skin wrinkles, the change rate of the skin elasticity R2 and the change rate of the skin tightness; rate of change = (post-use measurement-pre-use measurement)/(pre-use measurement x 100%;
5. the test results are shown in the following FIGS. 1-5 and tables 2-6:
TABLE 2 example 1 rate of change of skin wrinkle area before and after use
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Control | 3.60％ | -4.03％ | -0.40％ | -5.57％ |
| Example 1 | -9.29％ | -3.52％ | -3.94％ | -11.05％ |
TABLE 3 example 1 rate of change of skin wrinkle area Rate before and after use
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Control | 2.61％ | -4.97％ | -1.40％ | -6.88％ |
| Example 1 | -9.41％ | -3.59％ | -4.05％ | -11.15％ |
As shown in tables 2-3 and fig. 1-2, skin wrinkles (Visia-CR) were compared to before the samples were used: after 7 days of using the sample, the area of the corner wrinkles of the eye in the sample area is obviously reduced by 9.29%, and the area of the corner wrinkles of the eye in the control area is not obviously increased by 3.60%; the area rate of the canthus wrinkles in the sample area is obviously reduced by 9.41 percent, and the area rate of the canthus wrinkles in the control area is not obviously increased by 2.61 percent; after 14 days of using the sample, the area of the corner wrinkles of the sample area is not remarkably reduced by 3.52%, and the area of the corner wrinkles of the control area is not remarkably reduced by 4.03%; the area rate of the canthus wrinkles in the sample area is not obviously reduced by 3.59 percent, and the area rate of the canthus wrinkles in the control area is not obviously reduced by 4.97 percent.
After 28 days of using the sample, the area of the corner wrinkles of the eye in the sample area is reduced by 3.94% without significance, and the area of the corner wrinkles of the eye in the control area is reduced by 0.40% without significance; the area rate of the canthus wrinkles in the sample area is not remarkably reduced by 4.05 percent, and the area rate of the canthus wrinkles in the control area is not remarkably reduced by 1.40 percent; after 42 days of using the sample, the area of the corner wrinkles of the eye in the sample area is obviously reduced by 11.05 percent, and the area of the corner wrinkles of the eye in the control area is not obviously reduced by 5.57 percent; the area rate of the eye corner wrinkles in the sample area is remarkably reduced by 11.15%, and the area rate of the eye corner wrinkles in the control area is not remarkably reduced by 6.88%.
TABLE 4 example 1 rate of change of Ra of wrinkles on skin at the canthus before and after use
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Control | 0.43％ | 1.46％ | -0.27％ | 4.77％ |
| Example 1 | -1.49％ | -4.18％ | -5.38％ | -6.39％ |
As shown in table 4 and fig. 3, skin wrinkles (Primos) are compared to before use: after 7 days of using the sample, the Ra value of the eye angle wrinkles in the sample area is reduced by 1.49%, and the Ra value of the eye angle wrinkles in the control area is increased by 0.43%; after 14 days of using the sample, the Ra value of the eye angle wrinkles in the sample area is reduced by 4.18%, and the Ra value of the eye angle wrinkles in the control area is increased by 1.46%;
after 28 days of using the sample, the Ra value of the eye angle wrinkles in the sample area is reduced by 5.38%, and the Ra value of the eye angle wrinkles in the control area is reduced by 0.27%; after 42 days of use of the sample, the Ra value of the corner eye wrinkles in the sample area was significantly reduced by 6.39%, and the Ra value of the corner eye wrinkles in the control area was not significantly increased by 4.77%.
TABLE 5 example 1 rate of change of skin elasticity R2 before and after use
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Control | 0.28％ | -2.03％ | -3.30％ | -0.93％ |
| Example 1 | 8.48％ | 5.88％ | 5.27％ | 10.71％ |
As shown in table 5 and fig. 4, the skin elasticity R2 value is compared with that before use: after 7 days of using the sample, the skin elasticity R2 value of the sample area is obviously increased by 8.48 percent, and the skin elasticity R2 value of the control area is not obviously increased by 0.28 percent; after 14 days of using the sample, the skin elasticity R2 value of the sample area is remarkably increased by 5.88%, and the skin elasticity R2 value of the control area is not remarkably reduced by 2.03%; after 28 days of using the sample, the skin elasticity R2 value of the sample area is remarkably increased by 5.27%, and the skin elasticity R2 value of the control area is not remarkably reduced by 3.30%; after 42 days of application of the sample, the skin elasticity R2 value of the sample area is remarkably increased by 10.71%, and the skin elasticity R2 value of the control area is not remarkably reduced by 0.93%.
TABLE 6 example 1 rate of skin tightening change before and after use
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Control | 1.92％ | 1.71％ | 1.83％ | 1.49％ |
| Example 1 | 1.03％ | 1.42％ | 2.09％ | 1.50％ |
As shown in table 6 and fig. 5, the skin tightening change rate was higher than that before use: after 7 days of using the sample, the skin tightening F4 value of the sample area is not increased by 1.03%, and the skin tightening F4 value of the control area is not increased by 1.92%; after 14 days of using the sample, the skin tightening F4 value of the sample area is not increased by 1.42%, and the skin tightening F4 value of the control area is not increased by 1.71%; after 28 days of using the sample, the skin tightening F4 value of the sample area is not increased significantly by 2.09%, and the skin tightening F4 value of the control area is not increased significantly by 1.83%; after 42 days of use of the sample, the skin tightening F4 value of the sample area was not significantly increased by 1.50%, and the skin tightening F4 value of the control area was not significantly increased by 1.49%. The reduction in F4 value indicates an improvement in skin firmness, and the above results indicate that the effect of the embodiments of the present invention on skin firmness is not significant.
In combination with the partial subject example 1, the skin change pattern of the canthus before and after use (fig. 6), the area of the skin wrinkles around the eyes of the subject was significantly reduced after 14 days of using the inventive effect example for removing the canthus, and the canthus wrinkles were effectively smoothed after 42 days of use.
In conclusion, the eyeprint removing functional component used by the invention has good effect, and the embodiment of the invention has obvious effect of reducing eyeprint and can obviously improve the elasticity of skin.
Ophthalmic doctor clinical evaluation trial 2
1. The tester: 30 healthy people (20-45 years old), using example 1, women: the face has no obvious redness, skin damage, scars and the like;
2. test part: periocular region;
3. the evaluation criteria are shown in Table 7 below:
TABLE 7 ophthalmic clinical assessment scoring criteria table
The test results are shown in table 8 below:
TABLE 8 ophthalmic clinical evaluation results
During the use of the samples, 0 subjects developed adverse reactions at the eyelid, eyelid margin and eyelash, eyelid conjunctiva, cornea, anterior chamber, light reflex, etc.
Security verification 3
1. Number of test persons: 30 healthy persons (20-45 years old), test case sample 1 formula.
2. Test part: forearm curved side;
3. the testing method comprises the following steps: a suitable patch tester with the area not exceeding 50mm < 2 > and the depth of about 1mm is selected, and about 0.020-0.025 mL (g) of a test object is added into the patch tester by a closed patch test method. The patch tester was applied to the forearm of the subject, the test substance was removed after 24 hours, and skin reactions were observed at 0.5, 24, and 48 hours after the removal, and the results were recorded according to the skin reaction classification standard in cosmetic safety technical Specification 2015.
4. The evaluation criteria are shown in Table 9 below:
TABLE 9 skin reaction grading criteria
The results show that: the results of the human skin patch test showed that the score levels of 3 observation time points 0.5h, 24h and 48h after patch removal were all 0 points for 30 subjects. According to the specification of cosmetic safety technology (2015 edition), the test object does not cause adverse skin reaction to the subjects in the batch.
Synergistic test example 4
The amounts of the raw material component ratios of the eye-marking removing eye cream compositions of comparative examples 1 to 8 are shown in the following Table 10.
Table 10 proportion of raw material components (unit: mass%) of comparative examples 1 to 8
The preparation process flow of the moisturizing eye cream of comparative examples 1 to 8 is as follows:
1) Wetting and dispersing the thickener in water completely to obtain a mixed solution;
2) Adding the eye pattern removing functional components, the emollient, the filler and the preservative into the mixed solution in the step 1), heating to 65 ℃, homogenizing for 3 minutes at 3000r/min to enable the components to be completely dispersed;
3) Adding the emulsifying agent and the daily essence into the step 2), homogenizing for 3 minutes at 3000r/min to completely emulsify, and heating to 65 ℃ to obtain the eye cream composition with the eye wrinkle removing effect.
Test methods for eye creams of example 1 and comparative examples 1 to 8:
1. the tester: 90 healthy persons (20-45 years old), 9 groups of 10 persons each, women: the wrinkles at the outer canthus of the two sides are 1-3 grades (according to the Japanese wrinkles), and the face has no obvious redness, skin damage, scar and the like; examples 1 and comparative examples 1 to 8 were used, respectively;
2. test part: periocular region;
3. test instrument: visia is used for facial image acquisition. Visia-CR is used for facial image acquisition and wrinkle analysis.
4. The test indexes are as follows: rate of change of canthus wrinkle area;
5. the test results are shown in table 11 below:
the test of the effect of removing the eyeprint was conducted for example 1 and comparative examples 1 to 8, and the test results are shown in table 11.
TABLE 11 rates of change in the areas of wrinkles at the canthus before and after use for example 1 and comparative examples 1-8
| After 7 days of use | After 14 days of use | After 28 days of use | After 42 days of use | |
| Example 1 | -9.29％ | -10.52％ | -11.94％ | -11.95％ |
| Comparative example 1 | -4.02％ | -4.57％ | -4.97％ | -5.06％ |
| Comparative example 2 | -3.94％ | -4.35％ | -4.87％ | -4.93％ |
| Comparative example 3 | -4.21％ | -4.62％ | -5.13％ | -5.15％ |
| Comparative example 4 | -4.38％ | -4.94％ | -5.39％ | -5.57％ |
| Comparative example 5 | -1.53％ | -2.03％ | -2.12％ | -2.77％ |
| Comparative example 6 | -1.65％ | -2.11％ | -2.34％ | -2.98％ |
| Comparative example 7 | -1.16％ | -1.59％ | -1.93％ | -2.44％ |
| Comparative example 8 | -1.07％ | -1.34％ | -1.68％ | -2.15％ |
After 7 days of use, the change rate of the canthus wrinkle area is ranked as follows: example 1 > comparative example 4 > 3 > 1 > 2 > 6 > 5 > 7 > 8, the greater the change rate of the corner of the eye wrinkle area, the more remarkable the wrinkle improvement effect; after 42 days of use, the change rate of the canthus wrinkle area is ranked as follows: example 1 > comparative example 4 > 3 > 1 > 2 > 6 > 5 > 7 > 8.
The results show that the embodiment of the invention has the effects of short wrinkle removal cycle and obvious effect, and compared with the results of the comparative example, the various compositions for removing the eyewinker have synergistic effect.
The eye striae removing efficacy composition consists of snail secretion filtrate, a huperzia starburst algae extract, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, and the way of each component to play the role of striae removing is analyzed: the snail secretion filtrate in the composition permeates into subcutaneous tissue layer, collagen and elastin contained therein are effective in maintaining skin elasticity and moisture, and allantoin and glucuronic acid help skin resist free radical, make skin superficial layer of skin's viscose lipid soft, remove old cutin, accelerate cell regeneration, and reduce skin wrinkle and scar.
The extract of the Huperzia serrata is used for moisturizing, improving the repair process of the skin, and improving the adhesion between cells so that the skin tissue is more tightly and completely connected. Palmitoyl tripeptide-1 acts on the dermis layer, can promote the synthesis of extracellular matrixes such as collagen and glycosaminoglycan, strengthen the dermis layer, make the skin thicker, tighten, ease wrinkles and have stronger ultraviolet radiation resistance; palmitoyl tetrapeptide-7 supports the activation of skin repair processes, particularly the mastoid dermis, which is fragile and susceptible to UV damage, smoothing wrinkles while improving skin tone and elasticity.
The various eyeprint removing functional components are mutually synergistic, so that the active components act on the surface layer and the deep layer of the skin of the eyes, which is beneficial to reducing fiber cracking, in particular to helping the reconstruction of fiber reticular tissues of the mastoid dermis layer, effectively enhancing the toughness of the skin, improving the elasticity of the skin, tightening the skin of the eyes, smoothing the eyes and reproducing the youthful luster of the eyes.
In conclusion, the compound with the eye pattern removing effect has more obvious eye pattern removing effect through the synergistic effect among the components, and is more obvious than the eye pattern removing effect of the combination of two components and three components.
The foregoing description is only a preferred embodiment of the present invention and is not intended to limit the invention in any way, so any simple modification, equivalent variation and modification made to the above embodiment according to the technical matter of the present invention will still fall within the scope of the technical scheme of the present invention.
Claims (8)
1. An eye cream composition having an eye-print removing effect, characterized in that: based on the total weight of the composition, the composition consists of the following raw materials:
4.0-25% of eye wrinkle removing functional components, wherein the eye wrinkle removing functional components comprise: snail secretion filtrate 1-20%, palmitoyl tripeptide-1 1-20%, palmitoyl tetrapeptide-7 1-20% and Huperzia serrata extract 1-20%;
5.0-30.0% emollient;
0.5-30.0% of an emulsifier;
0.5-20.0% filler;
0.1-10.0% of a thickener;
0.3-5.0% preservative;
0.01-1.0% of daily essence and the balance of deionized water.
2. An eye cream composition with an eye-marking removing effect as claimed in claim 1, wherein: based on the total weight of the composition, the composition consists of the following components:
4.0-25% of eye wrinkle removing functional components, wherein the eye wrinkle removing functional components comprise: snail secretion filtrate 1-20%, palmitoyl tripeptide-1 1-20%, palmitoyl tetrapeptide-7 1-20% and Huperzia serrata extract 1-20%;
3. an eye cream composition with an eye-marking removing effect as claimed in claim 1, wherein: the eye wrinkle removing functional component comprises:
snail secretion filtrate 1-10%, palmitoyl tripeptide-1 1-10%, palmitoyl tetrapeptide-7 1-10% and Huperzia serrata extract 1-10%.
4. An eye cream composition with an eye-marking removing effect as claimed in claim 1, wherein: the eye wrinkle removing functional component comprises:
snail secretion filtrate 1.0-5%, palmitoyl tripeptide-1.0-5%, palmitoyl tetrapeptide-7.0-5% and Huperzia serrata extract 1.0-5%.
5. An eye cream composition with an eye-marking removing effect as claimed in claim 1, wherein:
the emollient is selected from at least one of caprylic/capric triglyceride, squalane, avocado oil, shea butter, glycerin, butylene glycol, hexylene glycol, 1, 2-pentanediol, methyl propylene glycol, C12-16 alcohol, polydimethylsiloxane, dimethiconol, PEG-11 methyl ether polydimethylsiloxane, phytosterol canola oil glyceride, hydrogenated polyisobutene, lecithin, polydecene, sodium hyaluronate, soybean oil, olive oil, isododecane, isohexadecane, stearyl alcohol, bisabolol, panthenol, and behenyl alcohol;
the emulsifier is at least one selected from olive oil PEG-7 esters, coconut oil PEG-10 esters, PEG-8 caprylic/capric glycerides, sorbitan olive oleate, stearic acid, palmitic acid, octyldodecanol, polysorbate-20, laureth-23, PEG-40 stearate, steareth-21, palmitols and mixtures of PEG-75 stearate and glyceryl stearate and steareth-20, tocopheryl acetate, soybean lecithin PC60, mixtures of glyceryl stearate and PEG-75 stearate, oleyl erucate, PEG-30 dimerized hydroxystearate, cetostearyl ether-25;
the filler is at least one selected from titanium dioxide, mica, boron nitride, maltodextrin, polymethylsilsesquioxane, diatomite, kaolin, cellulose acetate, starch octyl aluminum succinate, talcum powder, barium sulfate and volcanic ash;
the thickener is at least one selected from hydroxyethyl cellulose, xanthan gum, carbomer, sodium polyacrylate, acrylic acid (ester) copolymer, polymer EMT-10, polyacrylate crosslinked polymer-6, sodium acrylate/sodium acryloyldimethyl taurate copolymer, acrylic acid (ester) C10-30 alkanol acrylate crosslinked polymer, ammonium acryloyldimethyl taurate/VP copolymer, polyethylene and gum arabic.
6. A process for the preparation of an eye cream composition with an eye-marking removing effect according to any one of claims 1 to 5, characterized in that it comprises the following process steps:
1) Wetting and dispersing the thickener in water completely to obtain a mixed solution;
2) Adding the eye pattern removing functional components, the emollient, the filler and the preservative into the mixed solution in the step 1), heating to 65 ℃, homogenizing for 3 minutes at 3000r/min to enable the components to be completely dispersed;
3) Adding the emulsifying agent and the daily essence into the step 2), homogenizing for 3 minutes at 3000r/min to completely emulsify, and heating to 65 ℃ to obtain the eye cream composition with the eye wrinkle removing effect.
7. A cosmetic product characterized by: the cosmetic comprises the eye cream composition with the eye wrinkle removing effect prepared by the preparation method of claim 6.
8. The cosmetic product of claim 7, wherein: the cosmetic is in the form of solvent dispersion or suspension, or in the form of emulsified particles, or in the form of polymer packages.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126729.XA CN113786376B (en) | 2021-09-26 | 2021-09-26 | Eye cream composition with eye pattern removing effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126729.XA CN113786376B (en) | 2021-09-26 | 2021-09-26 | Eye cream composition with eye pattern removing effect and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113786376A CN113786376A (en) | 2021-12-14 |
| CN113786376B true CN113786376B (en) | 2024-02-23 |
Family
ID=78879337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111126729.XA Active CN113786376B (en) | 2021-09-26 | 2021-09-26 | Eye cream composition with eye pattern removing effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113786376B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114668887A (en) * | 2022-03-04 | 2022-06-28 | 上海臻臣化妆品有限公司 | Biological material and preparation method and application thereof |
| CN115006322B (en) * | 2022-06-06 | 2023-09-19 | 广东丸美生物技术股份有限公司 | Formula and preparation method of multifunctional eye mask with instant and long-acting effects |
| CN115120517B (en) * | 2022-08-22 | 2024-06-25 | 杨明振 | Preparation for removing eye wrinkles and eye bags, and preparation method and application thereof |
| CN115813832B (en) * | 2023-01-10 | 2024-04-05 | 麦吉丽生物科技有限公司 | Composition and eye cream for improving eye contour, and preparation method and application thereof |
| CN117618280B (en) * | 2024-01-26 | 2024-04-30 | 杭州译象生物科技有限公司 | Collagen anti-aging composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107961198A (en) * | 2017-12-08 | 2018-04-27 | 广州赛莱拉干细胞科技股份有限公司 | Eye cream containing stem cell secretory factors |
| CN110664692A (en) * | 2019-11-03 | 2020-01-10 | 上海悦目化妆品有限公司 | Eye cream for smoothing fine wrinkles and tightening skin |
| CN112022734A (en) * | 2020-09-23 | 2020-12-04 | 铂臻(广州)生物科技有限公司 | Eye tightening essence and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982097A (en) * | 2017-12-08 | 2018-05-04 | 广州赛莱拉干细胞科技股份有限公司 | Face cream containing stem cell secretion factors |
| CN107898657A (en) * | 2017-12-08 | 2018-04-13 | 广州赛莱拉干细胞科技股份有限公司 | Eye mask containing stem cell secretion factors |
| CN112206200A (en) * | 2020-09-18 | 2021-01-12 | 珠海海狮龙生物科技有限公司 | Full-effect crystal eye mask and preparation method thereof |
| CN112402310A (en) * | 2020-10-30 | 2021-02-26 | 广州市妆妍生物技术有限公司 | Vitreous chromogen polypeptide anti-wrinkle eye cream and preparation method thereof |
| CN112263524B (en) * | 2020-11-27 | 2022-09-06 | 湖北省麦诗特生物科技有限公司 | Cosmetic composition with multiple skin care effects and preparation method thereof |
| CN112587468A (en) * | 2020-12-28 | 2021-04-02 | 港都国际科技(北京)有限公司 | Multifunctional multiple-effect eye cream |
| CN113018223A (en) * | 2021-03-24 | 2021-06-25 | 湖北省麦诗特生物科技有限公司 | Eye tightening fatigue immunity eye cream composition containing coral algae compound and preparation method thereof |
-
2021
- 2021-09-26 CN CN202111126729.XA patent/CN113786376B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107961198A (en) * | 2017-12-08 | 2018-04-27 | 广州赛莱拉干细胞科技股份有限公司 | Eye cream containing stem cell secretory factors |
| CN110664692A (en) * | 2019-11-03 | 2020-01-10 | 上海悦目化妆品有限公司 | Eye cream for smoothing fine wrinkles and tightening skin |
| CN112022734A (en) * | 2020-09-23 | 2020-12-04 | 铂臻(广州)生物科技有限公司 | Eye tightening essence and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113786376A (en) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113786376B (en) | Eye cream composition with eye pattern removing effect and preparation method thereof | |
| CN110731924B (en) | Enhanced anti-aging cosmetic compositions | |
| CN111529417B (en) | Repairing eye cream with blue light resisting effect and preparation method thereof | |
| CN113730308B (en) | Eye cream composition containing blue light resistant liposome and preparation method thereof | |
| CN113893217B (en) | Face cream composition with freckle-removing effect and preparation method and application thereof | |
| CN113304075B (en) | Glacier rock cleaning oil control mud film and preparation method thereof | |
| CN113786362B (en) | Toning lotion composition with effects of relieving balance and protecting skin and preparation method thereof | |
| CN113693962A (en) | Fibronectin-containing multiple protein repair composition and preparation method thereof | |
| CN111053709A (en) | Emulsion for camellia seed oil mask, mask and preparation method of mask | |
| CN111920730A (en) | Repairing moisturizing cream and preparation method thereof | |
| CN113876665B (en) | Face cream composition with anti-wrinkle effect and preparation method and application thereof | |
| CN115154375A (en) | Stable cleaning composition with repairing and relieving effects | |
| CN113768853B (en) | Whitening and freckle-removing composition, and preparation method and application thereof | |
| CN106333880B (en) | toner based on thin emulsion and preparation method thereof | |
| CN113750028A (en) | Eye cream composition containing various water-replenishing and moisturizing effective components and preparation method thereof | |
| CN110075003A (en) | A kind of moisturizing content in freckle cream and preparation method thereof containing beta glucan | |
| CN110522712A (en) | A kind of bad face maintenance essence and preparation method | |
| CN113384482A (en) | Moisturizing and skin-tendering essence and preparation method thereof | |
| CN112842946A (en) | Cosmetic composition verified to have nerve soothing effect through electroencephalogram and preparation method thereof | |
| CN113730330B (en) | Eye cream composition with black eye removing effect and preparation method thereof | |
| CN112754963A (en) | Application method of firming anti-wrinkle skin care product | |
| CN113786361B (en) | Eye cream composition with pouch removing effect and preparation method thereof | |
| CN110859758A (en) | Whitening anti-aging repair type medical cold compress patch and preparation method thereof | |
| CN110025508A (en) | A kind of essence cream and preparation method thereof preventing striae of pregnancy generation | |
| CN108619018B (en) | Skin barrier repair cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |